These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 19786607)
1. Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Schmidt S; Sabarinath SN; Barbour A; Abbanat D; Manitpisitkul P; Sha S; Derendorf H Antimicrob Agents Chemother; 2009 Dec; 53(12):5039-45. PubMed ID: 19786607 [TBL] [Abstract][Full Text] [Related]
2. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686 [TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263 [TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Andes D; van Ogtrop ML; Peng J; Craig WA Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354 [TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA). Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of novel oxazolidinone analogs and 13 conventional antimicrobial agents against clinical isolates of Staphylococcus aureus in Beijing, China. Lei H; Jiang Y; Wang D; Gong P; Li Y; Dong Y; Dong M Jpn J Infect Dis; 2014; 67(5):402-4. PubMed ID: 25241696 [TBL] [Abstract][Full Text] [Related]
7. In vitro activities of linezolid and tigecycline against methicillin-resistant Staphylococcus aureus strains. Kaya O; Akcam FZ; Temel EN Microb Drug Resist; 2008 Jun; 14(2):151-3. PubMed ID: 18494600 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria. Oh SH; Kim J; Baek SY; Chae SE; Park HS; Cho YL; Kwak JH Molecules; 2017 Mar; 22(3):. PubMed ID: 28273820 [TBL] [Abstract][Full Text] [Related]
9. Oxazolidinone-containing Hybrids with Antibacterial Activity against Methicillin-resistant Staphylococcus aureus (MRSA): A Mini-review. Jiang D; Liu B; Gao T Curr Top Med Chem; 2021; 21(27):2440-2454. PubMed ID: 33185161 [TBL] [Abstract][Full Text] [Related]
10. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains]. Efe S; Sinirtaş M; Ozakin C Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917 [TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria. Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacological action and clinical effect of tedizolid phosphate (SIVEXTRO Mori M; Takase A Nihon Yakurigaku Zasshi; 2020; 155(5):332-339. PubMed ID: 32879176 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Boak LM; Li J; Rayner CR; Nation RL Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144 [TBL] [Abstract][Full Text] [Related]
16. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients. Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766 [TBL] [Abstract][Full Text] [Related]
17. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021 [TBL] [Abstract][Full Text] [Related]
18. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Jacqueline C; Navas D; Batard E; Miegeville AF; Le Mabecque V; Kergueris MF; Bugnon D; Potel G; Caillon J Antimicrob Agents Chemother; 2005 Jan; 49(1):45-51. PubMed ID: 15616274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]